Information on KRAS/BRAF genotype is extremely useful in systemic chemotherapy for advanced and recurrent CRC patients, not just for predicting the therapeutic efficiency of anti-EGFR therapy, but also for identifying patients with poor prognoses. Here, KRAS is linked to colorectal carcinoma.